公司概述
Arcutis Biotherapeutics, Inc. operates as a biopharmaceutical entity dedicated to the development and commercialization of therapeutic solutions specifically for dermatological diseases. The company functions within the healthcare sector and the biotechnology industry, positioning itself as a specialized player in the pharmaceutical landscape focused on skin conditions. As of the latest data, the enterprise holds a market capitalization of $3.05 billion, generates annual revenue of $376.07 million, and employs a workforce of 354 individuals. These valuation and revenue figures indicate that Arcutis has established a significant market presence with a substantial asset base, reflecting investor confidence in its pipeline of treatments for plaque psoriasis and atopic dermatitis, primarily driven by its lead product ZORYVE.
财务健康
The company reported revenue of $376.07 million over the trailing twelve months, with a net income of -$16,141,000 and an EBITDA of -$7,560,000. The substantial gap between positive revenue and negative net income reveals a cost structure characterized by high operating expenses, typical for a biotechnology firm in the commercialization phase where research, development, and sales costs exceed immediate profitability. Free cash flow stands at -$15,702,750, indicating that the company is currently consuming cash reserves rather than generating them, which limits immediate financial flexibility for external expansion without further capital raising. Profitability is further contextualized by a gross margin of 90.2%, an operating margin of 14.2%, and a profit margin of -4.3%, suggesting that while the core product is highly efficient to produce, overall operational expenses and R&D burdens have yet to be offset by net earnings. The balance sheet shows $220.98 million in cash against $114.52 million in debt, with a debt-to-equity ratio of 60.44, illustrating a leveraged position where liabilities are significant relative to equity but are partially cushioned by substantial cash holdings. Liquidity is robust, evidenced by a current ratio of 3.17, which indicates the company possesses more than three times the current assets necessary to cover its short-term obligations. Return on equity is recorded at -9.3% and return on assets at -2.0%, metrics that reveal that management effectiveness is currently challenged by the company's path to profitability rather than immediate value generation.
估值评估
Arcutis Biotherapeutics presents a forward P/E of 19.22, while the trailing P/E ratio is not available due to negative earnings, implying that the market is pricing the stock based on expected future profitability rather than historical performance. The price-to-book ratio stands at 16.00, indicating a significant market premium over the company's book value, which reflects high investor expectations for future growth from its dermatological pipeline. Alternative valuation metrics include a price-to-sales ratio of 8.10 and an EV/EBITDA of -389.03, suggesting that the market is willing to pay a high multiple for sales despite current losses, a common characteristic in biotechnology valuation where future revenue potential outweighs current cash flows. The stock has traded between a 52-week low of $11.86 and a 52-week high of $31.77, with the current trading price situated within this established range and reflecting the volatility inherent in small-cap biotech equities. The beta value is 1.77, which signifies that the stock's price volatility is substantially higher than that of the broader market, exposing investors to greater fluctuations in share price relative to overall market movements.
Growth & Income
Revenue growth year-over-year has accelerated to 81.5%, whereas earnings growth is not applicable due to the company's current net loss position, implying that top-line expansion is outpacing profitability in the early stages of commercialization. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, meaning it retains all earnings to reinvest into its growth initiatives rather than distributing income to shareholders. This reinvestment strategy is consistent with the operational profile of a biotechnology company prioritizing pipeline development and market penetration over immediate shareholder returns. The overall growth and income profile is defined by aggressive revenue expansion and zero dividend distribution, characteristic of a growth-oriented biopharmaceutical entity seeking to establish a foothold in the dermatology market before achieving sustained profitability.